Kancera: Underestimated optionality - Redeye

Redeye initiates coverage of Kancera, a Swedish life science company developing candidates targeting myocardial infarction and ovarian cancer. As clinical studies indicate a widely applicable treatment mechanism, we believe the stock market currently underestimates the upside optionality in the case.

Länk till analysen i sin helhet: https://www.redeye.se/research/1009668/kancera-underestimated-optionality?utm_source=finwire&utm_medium=RSS